Moving Forward From Monotherapy in HCC
Ann-Lii Cheng, MD, discusses where the of hepatocellular carcinoma is headed.
Ann-Lii Cheng, MD, distinguished professor in the Department of Internal Medicine, director at Graduate Institute of Oncology, and director, Department of Medical Oncology, National Taiwan University College of Medicine, discusses where the of hepatocellular carcinoma (HCC) is headed.
For the past 10 years, Cheng says the responses have really hit the ceiling in terms of monotherapy. About 15% to 20% of patients with HCC respond to monotherapies, meaning 75% to 80% of patients do not have a response.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
